# Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

> **NCT07285590** · PHASE2 · RECRUITING · sponsor: **Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea** · enrollment: 50 (estimated)

## Conditions studied

- Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** Pirtobrutinib and rituximab

## Key facts

- **NCT ID:** NCT07285590
- **Lead sponsor:** Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2032-12
- **Final completion:** 2032-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-16

## Collaborators

- Evidenze CRO
- Eli Lilly and Company

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285590, "Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07285590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*